Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19634803 | 0.89 | TDP1 (0.50) | ROCK2SIGMAR1TMEM97NR1H4MMP13 | |
| SCHEMBL21015872 | 0.89 | MRGPRX4 (0.51) | ROCK2SIGMAR1TMEM97NR1H4MMP13 | |
| SCHEMBL21015341 | 0.83 | NR1H4 (0.52) | ROCK2NR1H4MMP13HDAC6POLB | |
| SCHEMBL21015342 | 0.81 | ROCK2 (0.54) | ROCK2NR1H4MMP13HDAC6SMN1; SMN2 | |
| SCHEMBL21015486 | 0.80 | NR1H4 (0.38) | ROCK2NR1H4HDAC6POLBSMN1; SMN2 | |
| SCHEMBL21015963 | 0.80 | NR1H4 (0.47) | ROCK2NR1H4MMP13HDAC6POLB | |
| SCHEMBL21015314 | 0.80 | NR1H4 (0.49) | ROCK2NR1H4MMP13HDAC6POLB | |
| SCHEMBL19634804 | 0.79 | NR1H4 (0.48) | ROCK2NR1H4MMP13HDAC6SMN1; SMN2 | |
| SCHEMBL21015870 | 0.79 | HDAC6 (0.52) | ROCK2NR1H4MMP13HDAC6SMN1; SMN2 | |
| SCHEMBL21015316 | 0.78 | NR1H4 (0.55) | ROCK2NR1H4MMP13HDAC6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151403-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151403-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | MALT1, MYLK2, FKBP1B | ROCK2 3054/4885SIGMAR1 2494/4885TMEM97 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.